Clinical implications of the intrinsic molecular subtypes of breast cancer (Q26800996)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26253814 AND SRC:MED&resulttype=core&format=json

21 February 2020

review article

1 reference

title

Clinical implications of the intrinsic molecular subtypes of breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26253814 AND SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

Aranzazu Fernandez-Martinez

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26253814 AND SRC:MED&resulttype=core&format=json

21 February 2020

Ana Arance

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26253814 AND SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Aleix Prat

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26253814 AND SRC:MED&resulttype=core&format=json

21 February 2020

Estela Pineda

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26253814 AND SRC:MED&resulttype=core&format=json

21 February 2020

Barbara Adamo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26253814 AND SRC:MED&resulttype=core&format=json

21 February 2020

Patricia Galván

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26253814 AND SRC:MED&resulttype=core&format=json

21 February 2020

Lydia Gaba

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26253814 AND SRC:MED&resulttype=core&format=json

21 February 2020

Marc Díez

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26253814 AND SRC:MED&resulttype=core&format=json

21 February 2020

Margarita Viladot

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26253814 AND SRC:MED&resulttype=core&format=json

21 February 2020

Montserrat Muñoz

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26253814 AND SRC:MED&resulttype=core&format=json

21 February 2020

language of work or name

English

0 references

publication date

5 August 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26253814 AND SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26253814 AND SRC:MED&resulttype=core&format=json

21 February 2020

volume

24 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26253814 AND SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

S26-35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26253814 AND SRC:MED&resulttype=core&format=json

Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Epidemiology of basal-like breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Deconstructing the molecular portraits of breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Association between breast cancer subtypes and response to neoadjuvant anastrozole

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Predicting response and survival in chemotherapy-treated triple-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Comprehensive molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

APOBEC3B mutagenesis in cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Practical implications of gene-expression-based assays for breast oncologists.

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Defining the cellular precursors to human breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975.

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy al

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Association between CD8 T-cell infiltration and breast cancer survival in 12,439 patients

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Factors predicting late recurrence for estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

How many etiological subtypes of breast cancer: two, three, four, or more?

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Triple-negative breast cancer: risk factors to potential targets

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Predicting drug responsiveness in human cancers using genetically engineered mice.

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Supervised risk predictor of breast cancer based on intrinsic subtypes

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-bas

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Is adjuvant chemotherapy useful for women with luminal a breast cancer?

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Targeting adjuvant chemotherapy: a good idea that needs to be proven!

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Response-guided neoadjuvant chemotherapy for breast cancer.

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy.

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.BREAST.2015.07.008

7 January 2021

10.1016/J.BREAST.2015.07.008

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26253814 AND SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26253814 AND SRC:MED&resulttype=core&format=json